Premium
Intravenous Azithromycin‐Induced Ototoxicity
Author(s) -
Bizjak Eric D.,
Haug Marcus T.,
Schilz Robert J.,
Sarodia Bipin D.,
Dresing Janna M.
Publication year - 1999
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1592/phco.19.3.245.30930
Subject(s) - azithromycin , ototoxicity , medicine , dosing , antibiotics , pneumonia , intravenous antibiotics , community acquired pneumonia , antibacterial agent , anesthesia , chemotherapy , biology , microbiology and biotechnology , cisplatin
Intravenous azithromycin is increasingly administered for treatment of hospitalized patients with community‐acquired pneumonia. Macrolide antibiotics cause ototoxicity, which occurs most frequently when high serum concentrations are achieved. Current dosing guidelines for intravenous azithromycin can result in much higher serum concentrations than is seen with oral administration. We describe a 47‐year‐old woman who developed complete deafness after receiving 8 days of intravenous azithromycin.